Creative Planning Acquires Shares of 11,028 Kyverna Therapeutics, Inc. (NASDAQ:KYTX)

Creative Planning acquired a new stake in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 11,028 shares of the company’s stock, valued at approximately $54,000.

Other large investors also recently bought and sold shares of the company. DekaBank Deutsche Girozentrale acquired a new position in Kyverna Therapeutics in the first quarter valued at $181,000. Teachers Retirement System of The State of Kentucky acquired a new stake in shares of Kyverna Therapeutics during the first quarter worth about $313,000. Federated Hermes Inc. acquired a new stake in shares of Kyverna Therapeutics during the second quarter worth about $120,000. Rhumbline Advisers acquired a new stake in shares of Kyverna Therapeutics during the second quarter worth about $150,000. Finally, Skandinaviska Enskilda Banken AB publ boosted its stake in shares of Kyverna Therapeutics by 55.8% during the second quarter. Skandinaviska Enskilda Banken AB publ now owns 26,195 shares of the company’s stock worth $196,000 after buying an additional 9,385 shares during the period. Institutional investors and hedge funds own 18.08% of the company’s stock.

Kyverna Therapeutics Price Performance

NASDAQ KYTX opened at $5.06 on Thursday. Kyverna Therapeutics, Inc. has a 52-week low of $4.40 and a 52-week high of $35.06. The firm has a 50-day moving average price of $5.62 and a 200 day moving average price of $8.65.

Kyverna Therapeutics (NASDAQ:KYTX) last issued its earnings results on Monday, August 12th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.70) by $0.03. On average, analysts predict that Kyverna Therapeutics, Inc. will post -3.38 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Rodman & Renshaw assumed coverage on shares of Kyverna Therapeutics in a research note on Wednesday, October 9th. They set a “buy” rating and a $16.00 target price for the company. UBS Group assumed coverage on shares of Kyverna Therapeutics in a research note on Thursday, October 10th. They set a “buy” rating and a $13.00 target price for the company. HC Wainwright reiterated a “neutral” rating and set a $7.00 target price on shares of Kyverna Therapeutics in a research note on Thursday, September 19th. RODMAN&RENSHAW raised shares of Kyverna Therapeutics to a “strong-buy” rating in a report on Wednesday, October 9th. Finally, JPMorgan Chase & Co. cut their price target on shares of Kyverna Therapeutics from $39.00 to $33.00 and set an “overweight” rating for the company in a report on Wednesday, July 31st. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $28.71.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.